Pharmacokinetics and Prediction of Adverse Effects by EOB-MRI in the Treatment of Pancreatic Cancer with Gemcitabine + Nab-Paclitaxel

Pharmacokinetics and Prediction of Adverse Effects by EOB-MRI in the Treatment of Pancreatic Cancer with Gemcitabine + Nab-Paclitaxel - PK and Prediction of AE by EOB-MRI in the Treatment of Pancreatic Cancer with GnP

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054612

Enrollment

Registered

2024-06-08

Start date

2024-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer treated with GEM + nab PTX

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 over 18 years old 2 Pathological diagnosis of pancreatic cancer 3 Treat with GnP 4 Alive more than 3months 5 obtain informed consent

Exclusion criteria

Exclusion criteria: 1 Inability to perform contrast-enhanced CT or MRI due to renal dysfunction 2 Inability to undergo MRI examination due to claustrophobia 3 Already receiving treatment for peripheral neuropathy 4 Pregnant 5 Other subjects deemed inappropriate as research subjects by the principal investigator

Design outcomes

Primary

Measure	Time frame
CIPN events	—

Secondary

Measure	Time frame
OS,ORR,PFS,AEs	—

Countries

Japan

Contacts

Public ContactYusuke Takasaki

Juntendo Univ. dept of Gastroenterology

ytakasa@juntendo.ac.jp03-3813-3111

Outcome results